Jane Street Group LLC Invests $2.83 Million in Smith & Nephew plc (NYSE:SNN)

Jane Street Group LLC purchased a new position in shares of Smith & Nephew plc (NYSE:SNN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 115,182 shares of the medical equipment provider's stock, valued at approximately $2,831,000.

Other large investors also recently added to or reduced their stakes in the company. Franklin Resources Inc. boosted its holdings in Smith & Nephew by 16.8% during the third quarter. Franklin Resources Inc. now owns 114,080 shares of the medical equipment provider's stock worth $3,265,000 after buying an additional 16,397 shares in the last quarter. Crossmark Global Holdings Inc. lifted its stake in Smith & Nephew by 1.2% during the 4th quarter. Crossmark Global Holdings Inc. now owns 114,226 shares of the medical equipment provider's stock worth $2,808,000 after acquiring an additional 1,367 shares in the last quarter. Blue Trust Inc. boosted its position in Smith & Nephew by 26.0% in the 4th quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider's stock valued at $144,000 after buying an additional 1,213 shares during the period. R Squared Ltd purchased a new stake in shares of Smith & Nephew during the fourth quarter worth approximately $41,000. Finally, Bleakley Financial Group LLC raised its holdings in shares of Smith & Nephew by 3.5% in the 4th quarter. Bleakley Financial Group LLC now owns 17,704 shares of the medical equipment provider's stock valued at $435,000 after purchasing an additional 596 shares in the last quarter. 25.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. HSBC lowered shares of Smith & Nephew from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. StockNews.com raised Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 26th. Canaccord Genuity Group raised their price objective on shares of Smith & Nephew from $27.00 to $28.00 and gave the stock a "hold" rating in a research note on Thursday, May 1st. Hsbc Global Res lowered Smith & Nephew from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, UBS Group downgraded shares of Smith & Nephew from a "buy" rating to a "neutral" rating in a research report on Wednesday, March 12th. Six equities research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Smith & Nephew has a consensus rating of "Hold" and an average price target of $28.00.

Smith & Nephew Stock Up 0.8%

Smith & Nephew stock traded up $0.24 during mid-day trading on Tuesday, hitting $29.34. The company's stock had a trading volume of 38,585 shares, compared to its average volume of 800,172. The company has a market cap of $12.85 billion, a PE ratio of 13.55, a price-to-earnings-growth ratio of 1.26 and a beta of 0.68. The firm's 50 day moving average is $27.42 and its 200 day moving average is $26.29. Smith & Nephew plc has a 52-week low of $23.69 and a 52-week high of $31.72. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11.

Smith & Nephew Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be paid a $0.447 dividend. This represents a dividend yield of 2.5%. This is a boost from Smith & Nephew's previous semi-annual dividend of $0.29. The ex-dividend date of this dividend is Friday, March 28th. Smith & Nephew's payout ratio is presently 41.20%.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.